Novocure Announces 28 Presentations on Tumor Treating Fields from Externally Led Clinical Research and Analysis at 22nd Annual Meeting of the Society for Neuro-Oncology
In total, 60 abstracts on Tumor Treating Fields, including two oral presentations, will be presented
The volume of Tumor Treating Fields presentations marks a record number of abstracts for
ST. HELIER, Jersey–(BUSINESS WIRE)–
The presentations focus on the use of Tumor Treating Fields for a variety of brain cancers, and highlight data and trial designs from ongoing investigator-sponsored clinical trials program for Tumor Treating Fields. The trials studied Tumor Treating Fields in patients with newly diagnosed and recurrent glioblastoma, and as a potential treatment for pediatric gliomas, low-grade gliomas, meningioma, and brain metastases from non-small cell lung cancer. The trials included patients from the U.S.,
“We continue to see an increased external interest among the scientific community in exploring Tumor Treating Fields as a potential treatment option in a variety of solid tumor cancer types,” said Dr.
(QLIF-38) Tumor treating fields for the treatment of glioblastoma multiforme in daily praxis: experience from two hospitals in
(HOUT-06) TTFields for newly diagnosed Glioblastoma: Impact of consultation strategy. M. Proescholdt.
(NIMG-92) Volumetric response to TTFields in newly diagnosed GBM. C.F. Freyschlag.
(QLIF-32) Meeting the patients – meeting the needs: Platforms for patients using Optune® to exchange expertise. A.F. Keßler.
(PALL-01) One year with Optune® in
(QLIF-09) Longterm survival in glioblastoma patients after tumor treating fields (TTFields) therapy. A. Rulseh.
(NIMG-03) Quantitative MR measurements in glioblastoma patients: difference in mean diffusivity between Optune patients and patients with only standard treatment. J. Vymazal.
(QLIF-36) Role of nurses for the implementation of TTFields in daily clinical routine in glioblastoma treatment. M. Kilias.
(PDCT-07) Tumor treating fields for pediatric patients with high grade glioma: first case series in
(NIMG-67) Advanced perfusion and diffusion MR imaging in glioblastoma patients treated with tumor treating fields (TTFields) as first-line therapy.
(QLIF-42) Incidence and characterization of dermatologic adverse events in patients treated with tumor treating fields and impact on overall survival. A. Sumrall.
(QLIF-16) Clinical and Social Challenges & Opportunities in Treating Glioblastoma with Tumor Treatment Fields, a Case Series. M. Nguyen.
(ACTR-49) The effect of tumor treating fields in WHO grade 2 and 3 gliomas. N. Blondin.
(RARE-16) Case report: delayed development of pseudoprogression in 2 glioblastoma patients treated with TTFields. S. Hurrell.
(ACTR-43) Tumor treating field compliance and overall survival in patients with primary GBM. M. Pandey.
(RTHP-10) Impact of combination immunotherapy with tumor treating fields therapy in a glioma cohort. J. Schulte.
(SURG-04) Cranial bone defects in patients treated with TTFields: A case series. N. Thon.
(RTHP-26) Feasibility of a concomitant administration of alternating electric fields and radiotherapy – a planning study. C. Straube.
(ACTR-54) Open-label phase 1 clinical trial testing Personalized and Targeted Intervention with skull remodelling surgery to MAximize Levels of TTFields intensity for higher treatment benefit – the OptimalTTF study. A.R. Korshoej.
(ACTR-20) Finding a predictive marker for compliance to TTFields therapy – the comptune study.
(ACTR-40) Stereotactic radiosurgery and tumor treating fields in small cell lung cancer patients with limited brain metastases: a pilot and feasibility trial. C. Dulaney.
(ATIM-04) A Multi-Institutional Pilot Study of Prophylactic Cranial Tumor-Treating Fields for Patients with Extensive-stage Small Cell Lung Cancer. N. Rana.
(ATIM-07) Study of pembrolizumab, tumor treatment fields (Optune®) and temozolomide for older subjects with newly diagnosed glioblastoma. L. Donovan.
(ACTR-29) A Phase 2 Study of TTFields and Pulsed Bevacizumab in Patients with Bevacizumab-refractory Recurrent Glioblastoma. D. Tran.
(ACTR-62) A phase II study of tumor treating fields (TTFields) with temozolomide in patients with low-grade gliomas. T. Juarez.
(ACTR-19) A Phase 2 study of Tumor Treating Fields and Bevacizumab in Recurrent or Progressive Meningioma. P. Kumthekar.
(ACTR-44) Autopsy study on the effects of tumor treatment fields in recurrent glioblastoma: preliminary results and trial design. S. Hurrell.
(ACTR-73) A phase II study of tumor treating fields in combination with bevacizumab and temozolomide in patients with newly diagnosed, unresectable glioblastoma. A. Sumrall.
Headquartered in Jersey,
In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other words and terms of similar meaning. Novocure’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions as well as more specific risks and uncertainties facing
View source version on businesswire.com: http://www.businesswire.com/news/home/20171113005609/en/
Media and Investors:
Ashley Cordova, 212-767-7558